Journal News

Seeking to cure a coronavirus fatal to cats

Sneha Das
July 18, 2023

All of us have witnessed the impact of the COVID-19 pandemic caused by the SARS-CoV-2 coronavirus that claimed more than 6 million lives worldwide. The coronavirus family is made up of RNA viruses that infect many mammals and birds. In humans, outcomes can range from the common cold to fatal pandemics

Like humans, cats can be infected by coronaviruses. Most cats are exposed as kittens to the feline alphacoronavirus, or FCoV. One study found that 40% of domestic cats in the United Kingdom had antibodies for FCoV, suggesting prior infection. Most FCoV infections are asymptomatic or cause mild disease in the gastrointestinal tract. However, in 5% of cases, the virus spreads and results in a fatal disease called feline infectious peritonitis, or FIP. Experts believe that the gastrointestinal coronavirus strain can mutate into the more virulent virus that causes FIP.

Sheema Mir, an assistant professor at the Western University of Health Sciences in California studies infectious diseases caused by RNA viruses.

“FIP is a devastating disease that affects cats worldwide,” Mir said, “and currently, there are no effective treatments available for this condition.”

A coronavirus enters a host cell and multiplies there before exiting to infect new cells. Before the virus exits, it makes multiple copies of its RNA and packages it into its nucleocapsid, an outer shell that protects the viral RNA outside the host.

Mir’s group found that a novel compound called K31 targets the nucleocapsid protein of FCoV and stops it from multiplying. In cell culture models, the virus was undetectable 24 hours after treatment with a single dose of K31. The researchers reported this discovery in a recent paper published in the Journal of Biological Chemistry.

How does K31 inhibit the virus at the molecular level? When nucleocapsids are packaged with viral RNA, they form ribonucleocapsids, which coronaviruses rely on to make more copies of the viral RNA. K31 disrupts the structural integrity of these ribonucleocapsids, and this has a catastrophic effect on the virus within the host.

“Cell culture studies are useful for the initial screening of potential compounds, and this study provides a promising starting point,” Mir said. “The identification of K31 is an exciting development, but more research is needed to evaluate its effectiveness and safety in living animals.”

Mir’s group previously found that K31 inhibits the Andes virus and a new world hantavirus that causes hantavirus cardiopulmonary syndrome in humans. Initial cell culture studies suggest that K31 is well tolerated by host cells and might be developed into a broad-spectrum antiviral as well as an anti-coronavirus drug.

Previous drug development for coronaviruses has focused on targets such as RNA-dependent RNA polymerase, spike protein, and envelope protein, Mir said, but this study shows the nucleocapsid is also a druggable target.

FIP kills one in every 100–300 cats worldwide. According to Mir, targeted therapies with compounds like K31 could soon be an effective treatment with minimal side effects.

“It is exciting to see that our research project has identified a novel molecule that has potential for further development as an antiviral therapy,” Mir said. “It offers hope to cat owners.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Sneha Das

Sneha Das is a Ph.D. candidate in microbiology at the University of Illinois at Urbana–Champaign.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Insulin injections could one day be replaced with rock music
News

Insulin injections could one day be replaced with rock music

Nov. 26, 2023

Using mice, researchers engineered cells to release insulin in response to specific sound waves: the music of the band Queen.

From the journals: JBC
Journal News

From the journals: JBC

Nov. 24, 2023

Protein cleavage in polycystic kidney disease. Expanding tools to study ion channels. Mechanisms of 5-fluorouracil cytotoxicity and chemoresistance. Read about papers on these topics.

Detecting biomarkers for deadly lung disease
Journal News

Detecting biomarkers for deadly lung disease

Nov. 21, 2023

A group led by scientists from Genentech Inc is studying whether bioactive lipid species can predict idiopathic pulmonary fibrosis progression.

ASBMB journal events at #DiscoverBMB
Annual Meeting

ASBMB journal events at #DiscoverBMB

Nov. 21, 2023

The Journal of Biological Chemistry, the Journal of Lipid Research and Molecular & Cellular Proteomics are a big part of the society, so naturally they will be center stage in San Antonio.

Vampire viruses prey on other viruses to replicate themselves
News

Vampire viruses prey on other viruses to replicate themselves

Nov. 18, 2023

And they may hold the key to new antiviral therapies.

From the journals: MCP
Journal News

From the journals: MCP

Nov. 17, 2023

A new enzyme is unlocked in bacterial photosynthesis. A molecular target for alcohol consumption is uncovered. A special issue offers new perspectives in ECM research. Read about these recent papers.